SCHEMBL22235641

SCHEMBL22235641

CCOC(=O)N1C=CC(Cl)=NC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 3/20 0.35
HTT P42858 2/20 0.35
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
ALDH1A1 P00352 5/20 0.34
POLB P06746 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
ALOX15 P16050 1/20 0.34
LMNA P02545 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 2/20 0.33
ADRB2 P07550 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6192241 0.68 TSHR (0.33) KMT2AMAPTHTTL3MBTL1ALDH1A1
SCHEMBL22235983 0.68 GPR35 (0.36) KMT2AMAPTL3MBTL1ALDH1A1POLB
SCHEMBL10654652 0.67 SMN1; SMN2 (0.56) HRH1KMT2AMAPTL3MBTL1ALDH1A1
SCHEMBL6180556 0.66 ALDH1A1 (0.37) KMT2AMAPTL3MBTL1ALDH1A1POLB
SCHEMBL1014815 0.65 HTT (0.38) HRH1RAB9AKMT2AMAPTHTT
SCHEMBL27672566 0.64 ALDH1A1 (0.36) KMT2AMAPTHTTMAPK1L3MBTL1
SCHEMBL15056964 0.62 HDAC3 (0.41) RAB9AKMT2AMAPTMAPK1L3MBTL1
SCHEMBL28187319 0.61 ALDH1A1 (0.41) KMT2AMAPTHTTL3MBTL1ALDH1A1
SCHEMBL4771331 0.60 TSHR (0.35) KMT2AMAPTHTTL3MBTL1ALDH1A1
Bromide SCHEMBL29287371 0.60 LMNA (0.36) KMT2AMAPTHTTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089540-A1 COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2022-03-24 US disclosed
EP-3911309-A1 COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER Board Of Trustees Of Michigan State University (US) 2021-11-24 EP disclosed
WO-2020150668-A1 COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089540-A1 COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER PDCD1, CD274, PDCD1LG2 HRH1 2217/4885RAB9A 578/4885KMT2A 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.